ARTICLE
5 June 2025

Samsung Bioepis Secures Marketing Approval In Korea For Its Biosimilar To Amgen's Bone Cancer Drug Xgeva

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen's bone cancer drug XGEVA...
United States Food, Drugs, Healthcare, Life Sciences

Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen's bone cancer drug XGEVA, used to prevent fractures in those with bone metastases from solid tumors or multiple myeloma and to treat rare conditions like unresectable giant cell tumors. Earlier this year, Samsung also received approval in Korea for a biosimilar to PROLIA, Amgen's other denosumab product used to treat hormone-induced bone loss and postmenopausal osteoporosis.

We previously reported on FDA's approval of Samsung's denosumab biosimilars, OSPOMYV" (denosumab-dssb; 60 mg pre-filled syringe) and XBRYK" (denosumab-dssb; 120 mg vial), referencing Amgen's PROLIA® and XGEVA®, respectively, and the European Commission's marketing authorization of OBODENCE" (denosumab-dssb; 60 mg pre-filled syringe) and XBRYK" (denosumab-dssb; 120 mg vial), again referencing Amgen's PROLIA® and XGEVA®, respectively. With this domestic approval, Samsung has now secured regulatory approval for both of its denosumab biosimilars across all three major markets.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More